Assertio Holdings, Inc.
$18.14
▼
-3.37%
2026-04-21 05:26:00
www.assertiotx.com
NCM: ASRT
Explore Assertio Holdings, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$116.08 M
Current Price
$18.14
52W High / Low
$20.45 / $8.55
Stock P/E
—
Book Value
$14.63
Dividend Yield
—
ROCE
-12.35%
ROE
-28.25%
Face Value
—
EPS
$-4.74
Exp Qtr EPS
—
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Employees
53
Beta
0.43
Debt / Equity
42.84
Current Ratio
1.7
Quick Ratio
1.51
Forward P/E
6.96
Price / Sales
0.98
Enterprise Value
$92.99 M
EV / EBITDA
7.28
EV / Revenue
0.78
Rating
None
Target Price
$34
EPS Forecast (FY)
—
Pros
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Regencell Bioscience Holdings Limited | $29.09 | — | $13.89 B | — | -57.45% | -54.81% | $83.6 / $0.7 | $0.01 |
| 2. | Alkermes plc | $34.23 | 23.69 | $5.73 B | — | 13.07% | 14.72% | $36.48 / $25.16 | $10.99 |
| 3. | InterCure Ltd. | $0.75 | — | $125.93 M | — | -8.41% | -16.68% | $605 / $225.3 | $7.59 |
| 4. | Shuttle Pharmaceuticals Holdings, Inc. | $0.99 | — | $5.7 M | — | -791.36% | -7.91% | $11.25 / $0.5 | $1.13 |
| 5. | Aytu BioPharma, Inc. | $2.58 | — | $27.69 M | — | 4.15% | -1.09% | $3.06 / $0.98 | $1.32 |
| 6. | Supernus Pharmaceuticals, Inc. | $51.25 | — | $2.92 B | — | -3.31% | -3.68% | $59.68 / $29.16 | $18.48 |
| 7. | Hims & Hers Health, Inc. | $28.91 | 56.32 | $6.55 B | — | 6.03% | 25.23% | $70.43 / $13.74 | $2.38 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 13.54 M | 49.46 M | 29.22 M | 26.49 M | 32.18 M | — |
| Operating Profit | -9.15 M | 12.9 M | -8.04 M | -12.94 M | -8.8 M | — |
| Net Profit | -11.93 M | 11.45 M | -16.35 M | -13.54 M | -10.48 M | — |
| EPS in Rs | -1.85 | 1.77 | -2.53 | -2.1 | -1.62 | — |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 118.71 M | 124.96 M | 152.07 M | 156.23 M |
| Operating Profit | -17.22 M | -18.78 M | 16.04 M | 58.09 M |
| Net Profit | -30.38 M | -21.58 M | -331.94 M | 109.62 M |
| EPS in Rs | -4.71 | -3.34 | -51.42 | 16.98 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 266.97 M | 284.73 M | 286.42 M | 413.91 M |
| Total Liabilities | 173.02 M | 163.65 M | 148.42 M | 188.19 M |
| Equity | 93.95 M | 121.08 M | 138 M | 225.72 M |
| Current Assets | 216.65 M | 202.55 M | 171.06 M | 132.26 M |
| Current Liabilities | 127.51 M | 114.69 M | 93.44 M | 95.32 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -28.18 M | 26.41 M | 49.6 M | 78.6 M |
| Investing CF | -11.99 M | -48.91 M | 3.1 M | -42.67 M |
| Financing CF | -0.19 M | -0.35 M | -44.2 M | -7.79 M |
| Free CF | -28.18 M | 26.41 M | 48.98 M | 78.32 M |
| Capex | — | — | -0.63 M | -0.27 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | -17.83% | -2.67% | — | — |
| Earnings Growth % | 93.5% | -402.8% | — | — |
| Profit Margin % | -17.27% | -218.28% | 70.17% | — |
| Operating Margin % | -15.03% | 10.55% | 37.18% | — |
| Gross Margin % | 68.61% | 82.23% | 88% | — |
| EBITDA Margin % | 5.52% | -146.58% | 46.27% | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
| Date | Split |
|---|---|
| 2025-12-26 | 1:0.0666667 |
| 2021-05-18 | 1:0.25 |